Icon Plc (NASDAQ:ICLR) – Stock analysts at KeyCorp decreased their Q4 2017 earnings estimates for Icon in a research report issued to clients and investors on Tuesday. KeyCorp analyst D. Hooker now anticipates that the medical research company will post earnings per share of $1.39 for the quarter, down from their previous estimate of $1.41. KeyCorp currently has a “Buy” rating and a $130.00 target price on the stock.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The business had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same period last year, the firm posted $1.19 EPS. The company’s revenue was up 4.8% on a year-over-year basis.

Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. ValuEngine lowered shares of Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Jefferies Group raised their target price on shares of Icon from $122.00 to $132.00 and gave the company a “buy” rating in a report on Monday, October 9th. Barclays lifted their price objective on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Friday, October 27th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $123.00 price objective on shares of Icon in a research note on Thursday, October 12th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $121.82.

Icon (NASDAQ:ICLR) opened at $113.27 on Friday. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.90 and a quick ratio of 1.90. The firm has a market cap of $6,120.00, a price-to-earnings ratio of 21.99, a P/E/G ratio of 1.63 and a beta of 0.61.

Hedge funds and other institutional investors have recently bought and sold shares of the business. GRATRY & Co LLC boosted its stake in Icon by 5.1% during the third quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock worth $3,433,000 after buying an additional 1,474 shares during the period. GSA Capital Partners LLP lifted its position in shares of Icon by 116.3% during the second quarter. GSA Capital Partners LLP now owns 9,337 shares of the medical research company’s stock worth $913,000 after purchasing an additional 5,020 shares during the last quarter. BT Investment Management Ltd bought a new stake in shares of Icon during the third quarter worth $325,000. Insight Capital Research & Management Inc. bought a new stake in shares of Icon during the third quarter worth $1,359,000. Finally, NorthCoast Asset Management LLC lifted its position in shares of Icon by 23.4% during the third quarter. NorthCoast Asset Management LLC now owns 18,016 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 3,419 shares during the last quarter. 89.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “KeyCorp Weighs in on Icon Plc’s Q4 2017 Earnings (ICLR)” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/keycorp-weighs-in-on-icon-plcs-q4-2017-earnings-iclr/1806437.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with Analyst Ratings Network's FREE daily email newsletter.